-

$undefined

N/A

(N/A)

Sol-Gel NASDAQ:SLGL Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of inflammatory lesions of rosacea. The Company's pipeline also includes SGT-210 (erlotinib gel), under investigation for the treatment of palmoplantar keratoderma, and three pre-clinical assets - erlotinib, tapinarof and roflumilast - currently being tested for various pharmaceutical indications.

Location: Weizmann Science Park, Ness Ziona, 7403650, Israel | Website: www.sol-gel.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-11.25M

Cash

28.05M

Avg Qtr Burn

N/A

Short % of Float

0.06%

Insider Ownership

65.17%

Institutional Own.

24.02%

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EPSOLAY® (benzoyl peroxide) Cream Details Papulopustular Rosacea	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TWYNEO® (benzoyl peroxide and tretinoin) Cream, 3%/0.1% Details Acne Vulgaris	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SGT-610 (Patidegib) Details Gorlin Syndrome, Basal cell carcinoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SGT-210 (Erlotinib) Details Pachyonychia congenita, Skin disease/disorder	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.